



AUTOIMMUNE CHALLENGES IN HEPATO BILIARY MEDICINE

PROF.DR.M.REZAUL KARIM

PROF.OF MEDICINE DMC.


- 
- The background is a solid blue gradient. In the corners, there are decorative white line art elements resembling circuit boards or neural networks, with lines and small circles connecting them.
- Auto immune hepatitis
 - Epidemiology
 - Clinical Presentation
 - Diagnostic Evaluation
 - Treatment
 - Prognosis

DEFINITION

- Autoimmune hepatitis is a chronic inflammatory disease, generally characterized by circulating autoantibodies and elevated serum globulin level.
- The disease may start as acute hepatitis and may progress to chronic liver disease and Cirrhosis.
- Can occur at any age and ethnic group, predominantly affects female.

EPIDEMIOLOGY

- Mostly Females are affected (F : M = 4–10 : 1)
- Worldwide incidence of AIH is 0.7 – 2.0 per 100,000
- Prevalence is 4 – 25 per 100,000





Classification


is based on type of autoantibodies:

- Type 1
 - positive ANA and ASMA (classic form, responds well to steroids)
- Type 2
 - positive LKM-1 (typically female children and teenagers; disease can be severe), LKM-2 or LKM-3;
- Type 3
 - positive antibodies against soluble liver antigen(anti-SLA)
- Type 4
 - No Autoantibodies detected (~20%)

- 
- 
- 
- 
- Mainly Two types of AIH – Type 1 and Type 2.
 - Type 1 AIH is associated with ANA, ASMA, AAA, other autoantibodies like p-ANCA,
 - Type 2 AIH is associated with AKLM-1 and or ALC-1.
 - Overlap syndromes can occur with features of both autoimmune hepatitis and primary biliary cholangitis or primary sclerosing cholangitis.



- 
- The background is a solid blue gradient. In the corners, there are decorative white line art elements resembling circuit boards or neural networks, with lines and small circles connecting them.
- AIH is caused by environmental trigger in a genetically predisposed individual.
 - At molecular level it is thought to be the antigen,MHC complex and T cell receptors.
 - Viruses drugs ,herbs and immunization have been suggested as triggering agents.

- 
- The slide features a blue gradient background with abstract, light blue circuit-like lines in the corners. These lines consist of vertical and horizontal segments connected by small circles, resembling a stylized network or wiring diagram.
- Most evidence suggests a central role for an alteration in T cell function , alteration in B cell function is also important.
 - Escape from normal suppression of self reactive T cells, which results in ongoing inflammation and necrosis.

CLINICAL FEATURES



- AIH may present as

Acute Hepatitis

Cirrhosis

Acute Liver Failure

Acute or Chronic Liver disease with fluctuating Pattern

Some pt asymptomatic, vague ill health.

Risk Factors for Autoimmune Hepatitis



SCLEROSING
CHOLANGITIS


TYPE 1
DIABETES



ULCERATIVE
COLITIS

RHEUMATOID
ARTHRITIS



- 
- The background is a solid blue gradient. In the corners, there are decorative white line art elements resembling electronic circuit boards or neural network connections. These lines are thin and connect to small white circles at various points.
- AIH may present with some Extra hepatic disease Like
 - Autoimmune Thyroiditis
 - Rheumatoid Arthritis
 - Type I DM
 - Ulcerative Colitis, Celiac Disease
 - SLE

- Skin Lesions associated with AIH
- Can occur anytime in the course of disease
- Rashes seen 8–17% of patients


Most Commonly as transient and nonspecific Maculo popular rash


over the Face ,Trunk, Upper arm.

Associated Skin Lesion may be
Psoriasis,Vitiligo,Urticaria,Acne,Lichen Planus,Erythema Nodosum
and Pyoderma Gangrenosum.

INVESTIGATIONS

- Liver Enzymes
- In Acute Presentation ALT,AST may exceed 10 to 20 times
- Ratio of Alp to ALT/AST 1.5 to 5 times
- Gamma globulins Increase in gamma globulins
- Auto Antibodies
- ANA titre of 1:80 to 1: 100 or more is significant.



- 
- ASMA in the titre 1:80 or more is significant
 - ASMA more than 1:320 reflects presence of AAA.
 - Anti SLA/LP found in 10– 30% pts.
 - ANCA found in some patients.
 - AMA found in 8–12% cases
 - Anti DNA antibodies can be found in some pts.
- 

- Histology: Portal Mononuclear cell infiltrate

Periportal lesion(piecemeal or Interface hepatitis)

Bile duct changes Ductal injury or ductal destruction

>80% pt.

Plasma cell infiltrate,rosettes of hepatocytes

Some degree of fibrosis.

DIAGNOSTIC CRITERIA



- In a pt with compatible clinical presentation
- AST and/ALT at least 2 times the upper limit.
- A minimum of one +ve lab test, Increased IgG and or ANA,ASMA at a titre of at least 1: 40.
- Exclusion of disease that have similar clinical presentation like Acute viral hepatitis,drug induced liver injury and Alcoholic liver disease.
- Liver biopsy


Feature/parameter	Discriminator	Score
ANA or SMA+	$\geq 1:40$	+1*
ANA or SMA+	$\geq 1:80$	+2*
or LKM+	$\geq 1:40$	+2*
or SLA/LP+	Any titer	+2*
IgG or γ -globulins level	>upper limit of normal	+1
	>1.1x upper limit	+2
Liver histology (evidence of hepatitis is a necessary condition)	Compatible with AIH	+1
	Typical of AIH	+2
	Atypical	0
Absence of viral hepatitis	No	0
	Yes	+2

DIAGNOSTIC SCORING SYSTEM

- Based on
- Autoantibodies ANA/ASMA 1:40 **Point 1**. Titre 1:80 **point 2**.
- IgG titre > 1:10 **Point 2**.
- Liver histology Histologic features compatible with Auto immune hepatitis **Point 1**. Auto immune hepatitis typical histologic pattern **Point 2**.
- Absence of viral hepatitis: Absence of viral hepatitis **Point 2**.

Autoimmune Hepatitis: Tenets of Disease







DIFFERENTIAL DIAGNOSIS

- Primary biliary cholangitis
- Overlap syndrome
- Other causes of Hepatitis ; Viral Hepatitis, Drug Induced liver injury NASH, SLE associated liver disease. Acute Liver Failure, Iron overload.

TREATMENT

- Most patients with AIH respond well to steroids and AZA, with the liver blood tests becoming normal within several months. However, in some patients, the inflammation is more difficult to treat. In these cases, mycophenolate is usually tried next and then tacrolimus.





PROGNOSIS

- The chances for success are higher if the enzymes and IgG are normal for 2 years first.
- Up to 80% of patients will have their immune disease become active after medications are stopped .
- It is not easy to predict when this will occur, although it often happens in the first year. Because it could occur months to years after treatment has been stopped, liver blood tests to check for relapse must be done at regular intervals forever.

